PLA2R1 Proteine (PLA2R1)

Mouse (Murine) phospholipase A2 Receptor 1, 180kDa (PLA2R1) Interaktionspartner

1. PLA2R1 is increased in the airway epithelium in asthma, and serves as a regulator of airway hyperresponsiveness, airway permeability, antigen sensitization, and airway inflammation.

2. Study showed that CTLD1-2 as well as the FNII domain of PLA2R were responsible for binding to collagen I and collagen-dependent migration in both mouse and human PLA2R.

3. PLA2R might play a pathogenic role in myocardial infarction of PLA2R-deficient mice, through impaired healing of the infarcted region.

4. PLA2R deficiency increased sPLA2 (zeige PLA2G2A Proteine)-IB and -X levels in the lung through their impaired clearance from the lung, leading to exaggeration of lung inflammation induced by OVA treatment in a murine model.

Human phospholipase A2 Receptor 1, 180kDa (PLA2R1) Interaktionspartner

1. Five SNPs around the PLA2R1 gene were significantly associated with idiopathic membranous nephropathy.

2. Several risk alleles related to the PLA2R1 gene and within the HLA loci have been identified, whereas epitope spreading of PLA2R may predict treatment response. More recently, thrombospondin type 1 domain-containing 7A (THSD7A (zeige THSD7A Proteine)) antibodies have been discovered in primary membranous nephropathy .

3. PLA2R may play a role in some adolescent and preteen idiopathic membranous nephropathy patients but may be less frequently associated with idiopathic membranous nephropathy during childhood

4. Anti-M-type phospholipase A2 (zeige YWHAZ Proteine) receptor (anti-PLA2R) and anti-THSD7A (zeige THSD7A Proteine) (thrombospondin type-1 domain-containing 7A) were detected only in membranous neurophathy (MN) patient sera and not in controls.

5. The frameshift mutation detected in the current study would result in premature stops of amino acid synthesis in PLA2R1 and SRPK1 (zeige SRPK1 Proteine) proteins and hence resembles a typical inactivating mutation.

6. Single-nucleotide polymorphism in PLA2R1 gene is associated with primary membranous nephropathy.

7. blocking the ERRalpha (zeige ESRRA Proteine)-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERRalpha (zeige ESRRA Proteine) and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 (zeige JAK2 Proteine) pathway leading to oncosuppression.

8. Assessment of PLA2R autoimmunity is essential for patient management. Combination of PLA2R-Ab and PLA2R-Ag increases diagnosis sensitivity. PLA2R-Ab titer is a biomarker of disease severity at initial assessment, and the kinetics of the antibody are significantly correlated to disease evolution.

9. analysis of Japanese patients reveals that anti-PLA2R antibodies are present in idiopathic membranous nephropathy but not in secondary membranous nephropathy

10. Retrospective study to compare the value of serum anti-PLA2R antibody and glomerular PLA2R deposition in reflecting disease activity and renal function in Chinese patients with membranous nephropathy; serum anti-PLA2R antibody is more closely correlated with disease activity and renal function than glomerular PLA2R deposition.